Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
June 03, 2021 07:00 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
May 27, 2021 10:00 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the...
Innovation Pharma Files Form 10-Q; Patient Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19 Tops 70 Percent
May 13, 2021 08:00 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces the filing of its SEC Form...
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
April 28, 2021 08:00 ET | Innovation Pharmaceuticals Inc.
>60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trialWith COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than...
Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
April 14, 2021 09:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the...
Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
April 07, 2021 09:30 ET | Innovation Pharmaceuticals Inc.
Growing body of in vitro data support Brilacidin’s potential as a broad-spectrum inhibitor of virusesBrilacidin is currently undergoing Phase 2 clinical testing against COVID-19 in hospitalized...
Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 05, 2021 07:30 ET | Innovation Pharmaceuticals Inc.
Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendationEnrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial WAKEFIELD,...
Innovation Pharma’s COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
March 10, 2021 07:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine...
Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19
March 05, 2021 11:31 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now...
Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin
March 02, 2021 09:00 ET | Innovation Pharmaceuticals Inc.
Emerging mutations to the coronavirus are unlikely to affect Brilacidin’s ability to inhibit the virusBrilacidin currently is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19...